In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 1 to 25 of 294

Sort by

Guidance programme: Technology appraisal guidance`Remove $Guidance programme: Technology appraisal guidance filter`

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
12 SQ-HDM SLIT for treating allergic rhinitis caused by house dust mites in children 5 to 11 years [ID6510]	Technology appraisal guidance	26 August 2026
Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059]	Technology appraisal guidance	TBC
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer [TSID12065]	Technology appraisal guidance	TBC
Abicipar pegol for treating wet age-related macular degeneration [ID1533]	Technology appraisal guidance	TBC
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia [ID6232]	Technology appraisal guidance	18 June 2026
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]	Technology appraisal guidance	4 June 2026
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID6575]	Technology appraisal guidance	29 July 2026
ALXN1840 for treating Wilson disease [ID6422]	Technology appraisal guidance	TBC
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110]	Technology appraisal guidance	TBC
Apadamtase alfa for treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]	Technology appraisal guidance	TBC
Artificial intelligence (AI) technologies to assist histopathology for breast cancer diagnosis [ID6732]	Technology appraisal guidance	TBC
Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis [ID6684]	Technology appraisal guidance	TBC
Astegolimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6524]	Technology appraisal guidance	TBC
Asunercept for treating glioblastoma [ID1301]	Technology appraisal guidance	TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer [TSID10701]	Technology appraisal guidance	TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]	Technology appraisal guidance	TBC
Atezolizumab with BCG before surgery (neoadjuvant) for treating non-muscle-invasive bladder cancer [ID6667]	Technology appraisal guidance	TBC
Atogepant for treating migraine [ID6615]	Technology appraisal guidance	9 July 2026
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]	Technology appraisal guidance	TBC
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]	Technology appraisal guidance	TBC
Avacincaptad pegol for treating geographic atrophy caused by age-related macular degeneration [ID6401]	Technology appraisal guidance	TBC
Avapritinib for treating inadequately controlled moderate to severe indolent systemic mastocytosis [ID6578]	Technology appraisal guidance	3 September 2026
Avelumab for previously treated platinum-resistant ovarian cancer [ID1497]	Technology appraisal guidance	TBC

Results per page

10
25
50
All